Apellis Pharmaceuticals Inc
260 articles about Apellis Pharmaceuticals Inc
-
Apellis to Present Positive Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G at Kidney Week
10/17/2023
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® today announced that positive results from the Phase 2 NOBLE study investigating pegcetacoplan for the treatment of post-transplant recurrence of primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) and C3 glomerulopathy (C3G) will be presented at the American Society of Nephrology (ASN) Kidney Week Annual Meeting.
-
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 05, 2023
10/5/2023
Apellis Pharmaceuticals, Inc. announced that the company approved the grant of equity awards to seven new employees with a grant date of October 2, 2023, as equity inducement awards outside of the company's 2017 Stock Incentive Plan and material to the employees’ acceptance of employment with the company.
-
Apellis Announces Preliminary U.S. Net Revenues of Approximately $74 Million for SYFOVRE® (pegcetacoplan injection) in the Third Quarter of 2023
10/5/2023
Apellis Pharmaceuticals, Inc. provided an update on the launch of SYFOVRE® for geographic atrophy secondary to age-related macular degeneration.
-
Apellis Announces U.S. FDA Approval of the EMPAVELI® Injector, a Device to Streamline Self-Administration
10/2/2023
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has approved the EMPAVELI® Injector.
-
Apellis Receives Permanent J-Code (J2781) for SYFOVRE® (pegcetacoplan injection), Effective October 1, 2023
9/25/2023
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has assigned a permanent and product-specific J-code (J2781) for SYFOVRE ® (pegcetacoplan injection), the first-ever treatment for geographic atrophy (GA) secondary to age-related macular degeneration.
-
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 06, 2023
9/6/2023
Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in complement, announced that the company approved the grant of equity awards to 5 new employees with a grant date of September 1, 2023, as equity inducement awards outside of the company's 2017 Stock Incentive Plan and material to the employees’ acceptance of employment with the company.
-
Apellis Pharmaceuticals to Present at Upcoming September 2023 Investor Conferences
8/30/2023
Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in complement, announced that the company will participate in the following investor conferences.
-
Apellis Announces Corporate Restructuring to Drive Growth of SYFOVRE® (pegcetacoplan injection) and EMPAVELI® (pegcetacoplan), Positioning Company for Long-Term Success
8/29/2023
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) (the “Company”), a global biopharmaceutical company and leader in complement, today announced a corporate restructuring to drive growth of SYFOVRE® (pegcetacoplan injection) and EMPAVELI® (pegcetacoplan), positioning Apellis for long-term success.
-
After identifying structural variations in the 19-gauge filter needle included in some eye injection kits, Apellis has advised doctors to only use 18-gauge kits already in circulation and that will be distributed.
-
Apellis Provides Updates on Injection Kits and Rare Safety Events with SYFOVRE® (pegcetacoplan injection)
8/22/2023
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) (“the Company”) today provided an update on injection kits supplied by Apellis and an update on the rare events of retinal vasculitis reported in real-world treatment with SYFOVRE® (pegcetacoplan injection) for geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
-
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - August 04, 2023
8/4/2023
Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in complement, announced that the company approved the grant of equity awards to 13 new employees with a grant date of August 1, 2023, as equity inducement awards outside of the company's 2017 Stock Incentive Plan and material to the employees’ acceptance of employment with the company.
-
Syfovre has been linked to rare cases of eye inflammation that could lead to blinding, though Apellis’ review so far has found no connection between the treatment and the complications.
-
SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 30 Months in Patients with Geographic Atrophy (GA)
7/30/2023
Apellis Pharmaceuticals, Inc. announced data from the GALE extension study following 30 months of continuous treatment with SYFOVRE®, the first and only FDA approved treatment for geographic atrophy secondary to age-related macular degeneration.
-
Apellis Provides Update on Review of Rare Safety Events with SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy
7/29/2023
Apellis Pharmaceuticals, Inc. provided an update on its review of rare events of retinal vasculitis reported in real-world treatment with SYFOVRE® for geographic atrophy secondary to age-related macular degeneration.
-
Apellis Pharmaceuticals to Host Conference Call on July 31, 2023, to Discuss Second Quarter 2023 Financial Results
7/24/2023
Apellis Pharmaceuticals, Inc. today announced that the company will host a conference call and webcast to discuss its second quarter 2023 financial results on Monday, July 31, 2023, at 8:30 a.m. ET.
-
Apellis Announces Seven Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
7/10/2023
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced that seven abstracts will be presented as oral presentations at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting to be held July 28 to August 1 in Seattle.
-
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 06, 2023
7/6/2023
Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in complement, announced that the company approved the grant of equity awards to 11 new employees with a grant date of July 3, 2023, as equity inducement awards outside of the company's 2017 Stock Incentive Plan and material to the employees’ acceptance of employment with the company.
-
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 06, 2023
6/6/2023
Apellis Pharmaceuticals, Inc. announced that the company approved the grant of equity awards to five new employees with a grant date of June 1, 2023, as equity inducement awards outside of the company's 2017 Stock Incentive Plan and material to the employees’ acceptance of employment with the company.
-
The Massachusetts-based biopharma became the second company this week to drop its amyotrophic lateral sclerosis hopeful after it failed to elicit significant improvement compared with placebo.
-
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 5, 2023
5/5/2023
Apellis Pharmaceuticals, Inc. today announced that the company approved the grant of equity awards to 13 new employees with a grant date of May 1, 2023.